<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53466">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01662531</url>
  </required_header>
  <id_info>
    <org_study_id>CSL654_3002</org_study_id>
    <secondary_id>2011-006032-23</secondary_id>
    <nct_id>NCT01662531</nct_id>
  </id_info>
  <brief_title>A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B</brief_title>
  <official_title>A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the pharmacokinetics, safety and efficacy of rIX-FP for the control
      and prevention of bleeding episodes in children who have previously received factor
      replacement therapy for hemophilia B.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incremental recovery of rIX-FP</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2) of a single dose of rIX-FP</measure>
    <time_frame>Approximately 10 to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>Approximately 10 to 14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC to the last sample with quantifiable drug concentration (AUC0-t) of a single dose of rIX-FP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of a single dose of rIX-FP</measure>
    <time_frame>Approximately 10 to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects developing Factor IX (FIX) inhibitors</measure>
    <time_frame>Approximately 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The frequency of related adverse events</measure>
    <time_frame>Approximately 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects developing antibodies against rIX-FP</measure>
    <time_frame>Approximately 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of bleeding episodes requiring one, two or more than two infusions of rIX-FP to achieve hemostasis</measure>
    <time_frame>Approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of rIX-FP</measure>
    <time_frame>Approximately 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recombinant IX-FP consumed expressed as:
number of infusions per month and per year
IU/kg per month, per year and per event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>rIX-FP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) will be administered by IV infusion as routine weekly prophylaxis and episodic treatment for bleeding episodes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rIX-FP</intervention_name>
    <arm_group_label>rIX-FP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects, younger than 12 years old.

          -  Severe hemophilia B (Factor IX [FIX] activity of ≤ 2%).

          -  Body weight ≥ 10 kg.

          -  Subjects who have received FIX products (plasma-derived and/or recombinant FIX) for &gt;
             150 exposure days (EDs) (6 to &lt; 12 years), and &gt; 50 EDs (&lt; 6 years).

          -  No history of FIX inhibitor formation, no detectable inhibitors at Screening and no
             family history of inhibitors against FIX.

          -  Written informed consent for study participation.

        Exclusion Criteria:

          -  Known hypersensitivity to any FIX product or hamster protein.

          -  Known congenital or acquired coagulation disorder other than congenital FIX
             deficiency.

          -  Kidney or liver disease.

          -  Recent life-threatening bleeding episode.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Program Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registration Coordinator</last_name>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Henry Ekert Haemophilia Treatment Centre</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AKH Wien (Paediatrics)</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.R.T.H. Hop Bicetre (Hemophilie)</name>
      <address>
        <city>Le Kremlin-Bicetre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille (APHM) - Centre Ho</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Place du Docteur Baylac</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRC Coagulation Research Center GmbH</name>
      <address>
        <city>Duisburg/Altstadt</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unikinderklinik Frankfurt/Main</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hamburg-Eppendorf (Padiatr Hamat)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Maggiore (Centro emofilia e Trombosi)</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Bortolo, AULSS n.6 Vicenza</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>FGU &quot;Kirov Research Institute of Haemotology and Blood Trans)</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.U. A Coruna</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H.U. La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>August 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
